Nonetheless, although these therapies possess a high level of efficacy in ERBB2-positive breast cancer,33 we observed low overall use as recent as 2020 and a slow increase in uptake over time among all Medicare beneficiaries. The gene discussed is ERBB2; the disease is breast carcinoma.